MARKET

GALT

GALT

Galectin Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.680
-0.050
-1.83%
After Hours: 2.650 -0.03 -1.12% 16:00 10/20 EDT
OPEN
2.760
PREV CLOSE
2.730
HIGH
2.780
LOW
2.650
VOLUME
184.42K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.500
MARKET CAP
152.88M
P/E (TTM)
-7.8134
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
New Strong Sell Stocks for October 12th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Zacks · 10/12 13:11
These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright
Out on Wall Street, one group of stocks divides investors into either fans or critics. Penny stocks, or tickers that trade for less than $5 per share, are known for stirring up mixed reactions among market watchers, as these names are unrivaled in terms of both their risk and reward potential.Some argue
TipRanks · 10/06 20:30
CTI BioPharma, Genetron Holdings leads healthcare gainers, Aptorum Group, Adial Pharmaceuticals among major losers
Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon GloboCare (AVCO) -15%, Galectin Therapeutics (GALT) -15%, Windtree Therapeutics (WINT) -13%.
Seekingalpha · 09/30 15:00
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel LewisNORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced
GlobeNewswire · 09/29 17:00
Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options
Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.
Zacks · 09/29 13:52
Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020
Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel LewisNORCROSS, Ga., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced
GlobeNewswire · 09/22 13:04
Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference, on Monday, September 14
GlobeNewswire · 09/10 12:00
Insider Buys Galectin Therapeutics Stock
Shares of Galectin Therapeutics Inc (NASDAQ:GALT) moved higher by 8.3% from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, September 9 showed that Freeman Kevin D bought 5,000 shares at an average price of $2.57. The transaction moved the executive's stake in Galectin Therapeutics Inc. to 25,000 shares.
Benzinga · 09/09 15:46
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GALT. Analyze the recent business situations of Galectin Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GALT stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 11.36M
% Owned: 19.92%
Shares Outstanding: 57.04M
TypeInstitutionsShares
Increased
24
456.91K
New
18
170.21K
Decreased
16
178.04K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Director
Richard Uihlein
President/Chief Executive Officer/Director
Joel Lewis
Chief Financial Officer/Secretary
Jack Callicutt
Chief Operating Officer/Director
Harold Shlevin
Executive Vice President
Eliezer Zomer
Executive Director
Adam Allgood
Other
Pol Boudes
Other
J. Rex Horton
Director
James Czirr
Director
Elissa Schwartz
Director
Richard Zordani
Independent Director
Gilbert Amelio
Independent Director
Kary Eldred
Independent Director
Kevin Freeman
Independent Director
Gilbert Omenn
Independent Director
Marc Rubin
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GALT
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.